Global Nasal Drug Delivery Technology Industry

Global Nasal Drug Delivery Technology Industry

  • October 2019 •
  • 225 pages •
  • Report ID: 5799205 •
  • Format: PDF
Nasal Drug Delivery Technology market worldwide is projected to grow by US$25.4 Billion, driven by a compounded growth of 6.2%. Nasal Sprays, one of the segments analyzed and sized in this study, displays the potential to grow at over 7.3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$39.9 Billion by the year 2025, Nasal Sprays will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 7.1% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$1.1 Billion to the region’s size and clout in the next 5 to 6 years. Over US$1.2 Billion worth of projected demand in the region will come from Rest of Europe markets. In Japan, Nasal Sprays will reach a market size of US$3.2 Billion by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 5.9% over the next couple of years and add approximately US$4.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others, 3M Company; Aegis Therapeutics LLC; Aptargroup, Inc.; AstraZeneca PLC; GlaxoSmithKline PLC; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.